Consensus guides diagnosis and chemotherapy approaches for elderly patients with diffuse large b-cell lymphoma, highlighting tailored treatment strategies.
As the aging population increases, the proportion of elderly patients with diffuse large B-cell lymphoma (DLBCL) is significantly rising. Comprehensive geriatric assessment plays a crucial role in assessing chemotherapy tolerance. Very old or frail DLBCL patients classified by comprehensive geriatric assessment exhibit reduced tolerance to chemotherapy and multiple comorbidities, necessitating tailored treatment plans. To enhance the diagnostic and therapeutic capabilities of clinicians in China regarding very old or frail DLBCL patients classified by comprehensive geriatric assessment, the Lymphocyte Disease Group of the Hematology Division of the Chinese Medical Association and the Lymphatic Disease Society of the Chinese Medical Education Association have convened relevant experts to formulate this consensus.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: